134 related articles for article (PubMed ID: 33059322)
1. Solid lipid nanoparticles containing anti-tubercular drugs attenuate the Mycobacterium marinum infection.
Khatak S; Mehta M; Awasthi R; Paudel KR; Singh SK; Gulati M; Hansbro NG; Hansbro PM; Dua K; Dureja H
Tuberculosis (Edinb); 2020 Dec; 125():102008. PubMed ID: 33059322
[TBL] [Abstract][Full Text] [Related]
2. Formulation, optimization, and characterization of rifampicin-loaded solid lipid nanoparticles for the treatment of tuberculosis.
Chokshi NV; Khatri HN; Patel MM
Drug Dev Ind Pharm; 2018 Dec; 44(12):1975-1989. PubMed ID: 30058392
[TBL] [Abstract][Full Text] [Related]
3. Development and optimization of polymeric nanoparticles of antitubercular drugs using central composite factorial design.
Chawla R; Jaiswal S; Mishra B
Expert Opin Drug Deliv; 2014 Jan; 11(1):31-43. PubMed ID: 23802585
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of in silico designed inhibitors targeting MelF (Rv1936) against Mycobacterium marinum within macrophages.
Dharra R; Radhakrishnan VS; Prasad T; Thakur Z; Cirillo JD; Sheoran A; Pandey AK; Kulharia M; Mehta PK
Sci Rep; 2019 Jul; 9(1):10084. PubMed ID: 31300732
[TBL] [Abstract][Full Text] [Related]
5. Interfacial Phenomenon Based Biocompatible Alginate-Chitosan Nanoparticles Containing Isoniazid and Pyrazinamide.
Kushwaha K; Dwivedi H
Pharm Nanotechnol; 2018; 6(3):209-217. PubMed ID: 29938624
[TBL] [Abstract][Full Text] [Related]
6. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
[TBL] [Abstract][Full Text] [Related]
7. Encapsulation of Rifampicin in a solid lipid nanoparticulate system to limit its degradation and interaction with Isoniazid at acidic pH.
Singh H; Bhandari R; Kaur IP
Int J Pharm; 2013 Mar; 446(1-2):106-11. PubMed ID: 23410991
[TBL] [Abstract][Full Text] [Related]
8. Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation.
Garg T; Goyal AK; Rath G; Murthy RS
Pharm Dev Technol; 2016 Dec; 21(8):951-960. PubMed ID: 26334961
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of the effectiveness of lipid nanoparticle formulations loaded with anti-tubercular drugs combinations toward overcoming drug bioavailability in tuberculosis.
Banerjee S; Roy S; Bhaumik KN; Pillai J
J Drug Target; 2020 Jan; 28(1):55-69. PubMed ID: 31035816
[TBL] [Abstract][Full Text] [Related]
11. Streptomycin sulphate loaded solid lipid nanoparticles show enhanced uptake in macrophage, lower MIC in Mycobacterium and improved oral bioavailability.
Singh M; Schiavone N; Papucci L; Maan P; Kaur J; Singh G; Nandi U; Nosi D; Tani A; Khuller GK; Priya M; Singh R; Kaur IP
Eur J Pharm Biopharm; 2021 Mar; 160():100-124. PubMed ID: 33497794
[TBL] [Abstract][Full Text] [Related]
12. Optimization and characterization of ultrasound assisted preparation of curcumin-loaded solid lipid nanoparticles: Application of central composite design, thermal analysis and X-ray diffraction techniques.
Behbahani ES; Ghaedi M; Abbaspour M; Rostamizadeh K
Ultrason Sonochem; 2017 Sep; 38():271-280. PubMed ID: 28633826
[TBL] [Abstract][Full Text] [Related]
13. Lyophilized Nasal Inserts of Atomoxetine HCl Solid Lipid Nanoparticles for Brain Targeting as a Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD): A Pharmacokinetics Study on Rats.
Teaima MH; El-Nadi MT; Hamed RR; El-Nabarawi MA; Abdelmonem R
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259468
[TBL] [Abstract][Full Text] [Related]
14. Mycobacterium marinum infections in humans and tracing of its possible environmental sources.
Slany M; Jezek P; Fiserova V; Bodnarova M; Stork J; Havelkova M; Kalat F; Pavlik I
Can J Microbiol; 2012 Jan; 58(1):39-44. PubMed ID: 22182182
[TBL] [Abstract][Full Text] [Related]
15. Solid lipid nanoparticles for the controlled delivery of poorly water soluble non-steroidal anti-inflammatory drugs.
Kumar R; Singh A; Garg N; Siril PF
Ultrason Sonochem; 2018 Jan; 40(Pt A):686-696. PubMed ID: 28946474
[TBL] [Abstract][Full Text] [Related]
16. Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis.
Vieira ACC; Chaves LL; Pinheiro S; Pinto S; Pinheiro M; Lima SC; Ferreira D; Sarmento B; Reis S
Int J Pharm; 2018 Jan; 536(1):478-485. PubMed ID: 29203137
[TBL] [Abstract][Full Text] [Related]
17. Preparation, characterization, pharmacokinetics and tissue distribution of solid lipid nanoparticles loaded with tetrandrine.
Li S; Ji Z; Zou M; Nie X; Shi Y; Cheng G
AAPS PharmSciTech; 2011 Sep; 12(3):1011-8. PubMed ID: 21811889
[TBL] [Abstract][Full Text] [Related]
18. Fabrication and Characterization of Surface Engineered Rifampicin Loaded Lipid Nanoparticulate Systems for the Potential Treatment of Tuberculosis: An In Vitro and In Vivo Evaluation.
Chokshi NV; Rawal S; Solanki D; Gajjar S; Bora V; Patel BM; Patel MM
J Pharm Sci; 2021 May; 110(5):2221-2232. PubMed ID: 33610570
[TBL] [Abstract][Full Text] [Related]
19. Formulation of acyclovir-loaded solid lipid nanoparticles: design, optimization, and
El-Gizawy SA; El-Maghraby GM; Hedaya AA
Pharm Dev Technol; 2019 Dec; 24(10):1287-1298. PubMed ID: 31507232
[TBL] [Abstract][Full Text] [Related]
20. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
Pandey R; Sharma S; Khuller GK
Tuberculosis (Edinb); 2005; 85(5-6):415-20. PubMed ID: 16256437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
